Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Announces Validation of US Patent

Premium

Santaris Pharma announced this week that the US Patent and Trademark Office has issued a inter partes re-examination certificate for a US patent held by the company and covering locked nucleic acids.

According to the company, the USPTO ruling upholds the claims within the patent, which had been the subject of re-examination proceedings initiated at the request of Isis Pharmaceuticals.

The patent in question, No. 6,770,748, is a continuation-in-part of another US patent that had also previously been the subject of an Isis re-examination request, according to Santaris.

"We are delighted that these lengthy procedures have been successfully concluded with USPTO confirming the patentability of our … patents,” Santaris President and CEO Henrik Stage said in a statement. “These are two of our fundamental patents, which provide broad protection for our … antisense drug platform based on the locked nucleic acid/bicyclic nucleic acid chemistries."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.